Syndax Pharmaceuticals, Inc. Deferred Revenue (Non-Current)
Syndax Pharmaceuticals, Inc. (SNDX) had Deferred Revenue (Non-Current) of $15.79 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2018-05-09
- 2018-03-31: Deferred Revenue, Noncurrent $15.79M.
- 2017-12-31: Deferred Revenue, Noncurrent $16.76M.
- 2017-09-30: Deferred Revenue, Noncurrent $13.30M.
- 2017-06-30: Deferred Revenue, Noncurrent $13.61M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2018-03-31 | $15.79M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $16.76M 10-Q · filed 2018-05-09 |
| 2017-09-30 | $13.30M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $13.61M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $13.91M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $14.22M 10-K · filed 2018-03-08 |
| 2016-09-30 | $14.53M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $14.83M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $15.13M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $15.44M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |